To investigate the combinational effect of sorafenib and EGR1 overexpression on HCC growth, we detected the ATP levels in HCC cells after EGR1 overexpression, sorafenib treatment and the combinational treatment, the results showed single EGR1 overexpression or sorafenib treatment decreased ATP levels and the combinational treatment further reduced ATP production (Fig. 8B). Here, EGR1 is linked to hepatocellular carcinoma.